{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T19:14:15Z","timestamp":1769454855338,"version":"3.49.0"},"reference-count":42,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T00:00:00Z","timestamp":1769299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Zhejiang Provincial Natural Science Foundation of China","award":["LY24H290004"],"award-info":[{"award-number":["LY24H290004"]}]},{"name":"National Natural Science Foundation of China Youth Foundation","award":["81701969"],"award-info":[{"award-number":["81701969"]}]},{"name":"Natural Science Youth Exploration Program","award":["2022JKZKTS03"],"award-info":[{"award-number":["2022JKZKTS03"]}]},{"name":"Open fund for the State Key Laboratory of Pathogenic Biology of Animal Diseases","award":["SKLVEB2021KFKT002"],"award-info":[{"award-number":["SKLVEB2021KFKT002"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Tuberculosis (TB) remains a global public health emergency, with multidrug-resistant TB (MDR-TB) and rifampicin-resistant TB (RR-TB) posing critical challenges. Conventional longer regimens are characterized by suboptimal effectiveness, high toxicity, and poor tolerability. Consequently, there is an urgent demand for more effective, safer, shorter regimens with enhanced tolerability to replace traditional treatments. The present study aimed to systematically assess the effectiveness and safety of bedaquiline-containing modified shorter regimens (adaptations of the WHO-recommended 9\u201312-month bedaquiline-containing shorter regimen, with ethionamide, ethambutol, isoniazid, and pyrazinamide partially or fully substituted by linezolid, cycloserine\/terizidone, and\/or delamanid) for MDR\/RR-TB. Databases (PubMed, Cochrane Library, Embase, and Web of Science) were searched up to 17 December 2025. Data on treatment success, adverse events, and patient characteristics were extracted. Heterogeneity was assessed using Cochrane Q test and I2 statistic. Eleven studies involving 8166 patients were included. The pooled treatment success rate was 78.5% (95% CI: 0.69~0.87, I2: 98.45%; p = 0.00). The incidence of serious adverse events was 10.0%. Bedaquiline-containing modified shorter regimens may offer a potentially viable treatment option for MDR\/RR-TB patients, giving an option for patients who are ineligible for standardized regimens. In order to verify these findings, further large-scale trials are required.<\/jats:p>","DOI":"10.3390\/pathogens15020130","type":"journal-article","created":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T08:14:23Z","timestamp":1769415263000},"page":"130","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and Safety of Bedaquiline-Containing Modified Shorter Regimens for Multidrug- or Rifampicin-Resistant Tuberculosis: A Single-Arm Meta-Analysis"],"prefix":"10.3390","volume":"15","author":[{"given":"Yihui","family":"Zhou","sequence":"first","affiliation":[{"name":"The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5367-3813","authenticated-orcid":false,"given":"Hongxia","family":"Niu","sequence":"additional","affiliation":[{"name":"School of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/S0140-6736(19)30308-3","article-title":"Tuberculosis","volume":"393","author":"Furin","year":"2019","journal-title":"Lancet"},{"key":"ref_2","unstructured":"World Health Organization (2022). WHO Operational Handbook on Tuberculosis: Module 4: Treatment: Drug-Resistant Tuberculosis Treatment, 2022 Update ed., World Health Organization."},{"key":"ref_3","unstructured":"World Health Organization (2015). The End TB Strategy, World Health Organization."},{"key":"ref_4","unstructured":"World Health Organization (2022). WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment\u2014Drug-Resistant Tuberculosis Treatment, 2022 Update ed., World Health Organization."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2001394","DOI":"10.1183\/13993003.01394-2020","article-title":"Changes in Treatment for Multidrug-Resistant Tuberculosis According to National Income","volume":"56","author":"Kwak","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Shringarpure, K.S., Isaakidis, P., Sagili, K.D., Baxi, R.K., Das, M., and Daftary, A. (2016). \u201cWhen Treatment Is More Challenging than the Disease\u201d: A Qualitative Study of MDR-TB Patient Retention. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0150849"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","article-title":"A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis","volume":"380","author":"Nunn","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1901467","DOI":"10.1183\/13993003.01467-2019","article-title":"Standardised Shorter Regimens versus Individualised Longer Regimens for Rifampin- or Multidrug-Resistant Tuberculosis","volume":"55","author":"Abidi","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1700061","DOI":"10.1183\/13993003.00061-2017","article-title":"Effectiveness and Safety of Standardised Shorter Regimens for Multidrug-Resistant Tuberculosis: Individual Patient Data and Aggregate Data Meta-Analyses","volume":"50","author":"Salim","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"306","DOI":"10.2471\/BLT.19.243584","article-title":"Economic Evaluation of Short Treatment for Multidrug-Resistant Tuberculosis, Ethiopia and South Africa: The STREAM Trial","volume":"98","author":"Madan","year":"2020","journal-title":"Bull. World Health Organ."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/cid\/ciz263","article-title":"Eligibility for a Shorter Treatment Regimen for Multidrug-Resistant Tuberculosis in the United States, 2011\u20132016","volume":"70","author":"Tsang","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijid.2021.08.055","article-title":"Insignificant Difference in Culture Conversion between Bedaquiline-Containing and Bedaquiline-Free All-Oral Short Regimens for Multidrug-Resistant Tuberculosis","volume":"111","author":"Fu","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S1473-3099(24)00228-7","article-title":"Effectiveness and Safety of Modified Fully Oral 9-Month Treatment Regimens for Rifampicin-Resistant Tuberculosis: A Prospective Cohort Study","volume":"24","author":"Korotych","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4081\/monaldi.2021.1679","article-title":"Effectiveness and Safety of Fully Oral Modified Shorter Treatment Regimen for Multidrug-Resistant Tuberculosis in Georgia, 2019\u20132020","volume":"91","author":"Avaliani","year":"2021","journal-title":"Monaldi Arch. Chest Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijid.2022.11.007","article-title":"Effectiveness and Safety of Bedaquiline-Based, Modified All-Oral 9\u201311-Month Treatment Regimen for Rifampicin-Resistant Tuberculosis in Vietnam","volume":"126","author":"Nguyen","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/cid\/ciae305","article-title":"Safety and Effectiveness of 3 Novel All-Oral Shortened Regimens for Rifampicin- or Multidrug-Resistant Tuberculosis in Kazakhstan","volume":"79","author":"Rashitov","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez, M., Bustos, Y.C., Encarnaci\u00f3n, M., Mu\u00f1oz, E., De Los Santos, S., S\u00e1nchez, I., Portorreal, L., Sombie, S.B., Sall, F.B., and Merle, C.S. (2025). Evaluation of a Modified Short All Oral Treatment Regimen for Rifampicin-Multidrug Resistant Tuberculosis in Dominican Republic. BMC Infect. Dis., 25.","DOI":"10.1186\/s12879-024-10417-w"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e054434","DOI":"10.1136\/bmjopen-2021-054434","article-title":"Implementation of the \u201cRemoved Injectable Modified Short-Course Regimens for EXpert Multidrug Resistant Tuberculosis\u201d (RISE Study) in Tanzania: A Protocol for a Mixed-Methods Process Evaluation","volume":"12","author":"Kalolo","year":"2022","journal-title":"BMJ Open"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e088556","DOI":"10.1136\/bmjopen-2024-088556","article-title":"Patients\u2019 Acceptability, Adherence and Satisfaction on the Modified Shorter All-Oral Multidrug-Resistant Tuberculosis Regimen: A Two-Phase Cross-Sectional Study in Tanzania","volume":"15","author":"Lalashowi","year":"2025","journal-title":"BMJ Open"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5588\/pha.20.0026","article-title":"Adverse Events Using Shorter MDR-TB Regimens: Outcomes from Port Moresby, Papua New Guinea","volume":"11","author":"Mason","year":"2021","journal-title":"Public Health Action"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e018220","DOI":"10.1136\/bmjgh-2024-018220","article-title":"Impact of All-Oral Bedaquiline-Based Shorter Regimens in the Treatment of Drug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis","volume":"10","author":"Fekadu","year":"2025","journal-title":"BMJ Glob. Health"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"86","DOI":"10.11604\/pamj.2025.51.86.48418","article-title":"Treatment Outcomes among Patients with Drug-Resistant Tuberculosis Managed with BPaL\/BPaLM Regimen in the Southeast Zone of Nigeria","volume":"51","author":"Ikpe","year":"2025","journal-title":"Pan Afr. Med. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"17362","DOI":"10.1021\/acsomega.2c05511","article-title":"Potential Repurposed Drug Candidates for Tuberculosis Treatment: Progress and Update of Drugs Identified in Over a Decade","volume":"8","author":"Sharma","year":"2023","journal-title":"ACS Omega"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1056\/NEJMoa2400327","article-title":"Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis","volume":"392","author":"Guglielmetti","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., and Altman, D.G. (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med., 6.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref_26","unstructured":"World Health Organization (2013). Definitions and Reporting Framework for Tuberculosis\u20142013 Revision: Updated December 2014 and January 2020, World Health Organization."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1164\/rccm.202107-1779OC","article-title":"An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study)","volume":"205","author":"Esmail","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Song, Y., Shu, W., Pei, Y., Du, J., Wu, G., Wang, H., Mi, F., Liu, F., Ma, L., and Xie, L. (2024). Nine Months of Bedaquiline, Linezolid, Levofloxacin, Clofazimine, and Cycloserine Chemotherapy for Rifampicin\/Multidrug-Resistant Tuberculosis: A Multicenter, Randomized, Open-Label Non-Inferiority Trial in China. BMC Med., 22.","DOI":"10.1186\/s12916-024-03633-3"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/cid\/ciae145","article-title":"Treatment of Multidrug-Resistant or Rifampicin-Resistant Tuberculosis with an All-Oral 9-Month Regimen Containing Linezolid or Ethionamide in South Africa: A Retrospective Cohort Study","volume":"78","author":"Morgan","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1111\/tmi.70041","article-title":"All-Oral Shorter Treatment Regimens for Multidrug- and Rifampicin-Resistant Tuberculosis: Evaluating Their Effectiveness, Safety, and Impact on the Quality of Life of Patients in Lao PDR","volume":"30","author":"Iem","year":"2025","journal-title":"Trop. Med. Int. Health"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"108222","DOI":"10.1016\/j.ijid.2025.108222","article-title":"From trials to programmatic scale-up: Treatment outcomes of rifampicin-resistant tuberculosis during transition to short oral regimens in Vietnam (2021-2022)","volume":"163","author":"Nguyen","year":"2025","journal-title":"Int. J. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1093\/cid\/ciaf112","article-title":"Treatment Outcomes with an Oral Short Course Regimen for Rifampicin-Resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South Africa","volume":"81","author":"Stadler","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Fardhdiani, V., Trush, O., Lytvynenko, N., Pylypchuk, S., Terleeva, Y., Malakyan, K., Rupasinghe, P., Wally, Y., Duka, M., and Didyk, V.S. (2025). End of Treatment and 12-Month Post-Treatment Outcomes in Patients Treated with All-Oral Regimens for Rifampicin-Resistant Tuberculosis in Ukraine: A Prospective Cohort Study. PLoS Glob. Public Health, 5.","DOI":"10.1371\/journal.pgph.0003983"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e0203321","DOI":"10.1128\/aac.02033-21","article-title":"Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: A Modeling Study","volume":"66","author":"Liu","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e0144822","DOI":"10.1128\/aac.01448-22","article-title":"QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies","volume":"67","author":"Ali","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/S0140-6736(22)01883-9","article-title":"9 Months of Delamanid, Linezolid, Levofloxacin, and Pyrazinamide versus Conventional Therapy for Treatment of Fluoroquinolone-Sensitive Multidrug-Resistant Tuberculosis (MDR-END): A Multicentre, Randomised, Open-Label Phase 2\/3 Non-Inferiority Trial in South Korea","volume":"400","author":"Mok","year":"2022","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","article-title":"Delamanid for Multidrug-Resistant Pulmonary Tuberculosis","volume":"366","author":"Gler","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1700387","DOI":"10.1183\/13993003.00387-2017","article-title":"Effectiveness and Safety of Bedaquiline-Containing Regimens in the Treatment of MDR- and XDR-TB: A Multicentre Study","volume":"49","author":"Borisov","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/14740338.2018.1520837","article-title":"Moxifloxacin-Induced QT Interval Prolongation and Torsades de Pointes: A Narrative Review","volume":"17","author":"Khan","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e0104823","DOI":"10.1128\/spectrum.01048-23","article-title":"Effects of Bedaquiline Combined with Fluoroquinolone and\/or Clofazimine on QT Interval in Patients with Multidrug-Resistant Tuberculosis: A Retrospective Study","volume":"11","author":"Li","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S2213-2600(24)00300-X","article-title":"Towards Shorter, Safer, Flexible, and More Effective Treatment Regimens for Drug-Resistant Tuberculosis","volume":"12","author":"Dheda","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1093\/infdis\/jiad564","article-title":"A Bedaquiline, Pyrazinamide, Levofloxacin, Linezolid, and Clofazimine Second-Line Regimen for Tuberculosis Displays Similar Early Bactericidal Activity as the Standard Rifampin-Based First-Line Regimen","volume":"230","author":"Zainabadi","year":"2024","journal-title":"J. Infect. Dis."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/2\/130\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T08:45:39Z","timestamp":1769417139000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/15\/2\/130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,25]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["pathogens15020130"],"URL":"https:\/\/doi.org\/10.3390\/pathogens15020130","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,25]]}}}